BriaCell Therapeutics Corp.
BCTX
$2.02
-$0.05-2.42%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -224.13% | 8.05% | -25.77% | 76.40% | 67.30% |
| Total Depreciation and Amortization | 903.29% | 752.63% | 601.97% | 451.32% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 85.95% | 13.49% | -9.73% | -35,728.53% | -3,524.16% |
| Change in Net Operating Assets | -156.24% | 280.17% | 221.63% | 299.70% | 31.07% |
| Cash from Operations | 22.37% | 29.63% | 15.58% | -1.61% | -91.99% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.33% | -- | -- | -- | -- |
| Cash from Investing | -216.36% | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 807.76% | 439.68% | 309.32% | 10.43% | 249,900.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 807.76% | 439.68% | 309.32% | 11.75% | 2,046.47% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 142.32% | 95.48% | 67.01% | -3.02% | -66.50% |